<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402014000300009</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2014.02.002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Papel de la inflamación renal en la fisiopatología de la hipertensión sensible a sal]]></article-title>
<article-title xml:lang="en"><![CDATA[Role of renal inflammation in the physiopathology of salt-sensitive hypertension]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro Torres]]></surname>
<given-names><![CDATA[Yaniel]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos Portela]]></surname>
<given-names><![CDATA[Alejandro Emilio]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garrido B&#337;sze]]></surname>
<given-names><![CDATA[Ildiko María]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidad de Ciencias Médicas Dr. Serafín Ruiz de Zárate Ruiz Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Policlínico Universitario José Ramón León Acosta  ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2014</year>
</pub-date>
<volume>84</volume>
<numero>3</numero>
<fpage>211</fpage>
<lpage>217</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402014000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402014000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402014000300009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[La hipertensión sensible a sal es el aumento de la presión arterial luego de una sobrecarga salina, como consecuencia esencialmente de una disminución en la excreción renal de sodio. En los últimos años, ha sido desarrollada una teoría para explicar su origen que tiene como base la inflamación del tejido renal. El proceso inicia con la producción en los riñones de radicales libres derivados del metabolismo oxidativo. Luego se desarrolla un mecanismo de inflamación del intersticio renal por infiltración de linfocitos T, y otras células inmunológicas. Fundamentalmente los linfocitos T incrementan la producción de angiotensina II que estimula la retención de sodio y agua a este nivel, favoreciendo el desarrollo de hipertensión sensible a sal. La relación entre infiltración renal por células del sistema inmune e hipertensión sensible a sal permite, en parte, explicar la asociación entre enfermedades autoinmunes y la hipertensión arterial. El uso de antioxidantes y el diseño de nuevos fármacos pueden ser una alternativa adicional al tratamiento de los pacientes afectados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Salt-sensitive hypertension is produced by a decrease in salt renal excretion after a salt overload. Over the last few years, a new theory has been developed to explain this condition based on renal tissue inflammation. This process begins with free radicals production in renal tissue due to oxidative metabolism. Then they favor a renal inflammation mechanism with T-lymphocytes infiltration and other immune cells. Essentially, T-lymphocytes determine an increase in angiotensin II production which raises sodium and water retention. Association among autoimmune diseases and hypertension may be explained, in part, by the relationship between salt-sensitive hypertension and renal inflammation. The use of antioxidant drugs and the development of new medicaments may be a choice for treating patients affected with this condition.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hipertensión sensible a sal]]></kwd>
<kwd lng="es"><![CDATA[Estrés oxidativo]]></kwd>
<kwd lng="es"><![CDATA[Inflamación renal]]></kwd>
<kwd lng="es"><![CDATA[Linfocitos T]]></kwd>
<kwd lng="es"><![CDATA[Macrófagos]]></kwd>
<kwd lng="es"><![CDATA[Cuba]]></kwd>
<kwd lng="en"><![CDATA[Salt-sensitive hypertension]]></kwd>
<kwd lng="en"><![CDATA[Oxidative stress]]></kwd>
<kwd lng="en"><![CDATA[Renal inflammation]]></kwd>
<kwd lng="en"><![CDATA[T-lymphocytes]]></kwd>
<kwd lng="en"><![CDATA[Macrophages]]></kwd>
<kwd lng="en"><![CDATA[Cuba]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[  	    <p align="justify"><font face="verdana" size="4">Art&iacute;culo de revisi&oacute;n</font></p>  	    <p>&nbsp;</p>  	    <p align="center"><font face="verdana" size="4"><b>Papel de la inflamaci&oacute;n renal en la fisiopatolog&iacute;a de la hipertensi&oacute;n sensible a sal</b></font></p>  	    <p>&nbsp;</p>  	    <p align="center"><font face="verdana" size="3"><b>Role of renal inflammation in the physiopathology of salt&#45;sensitive hypertension</b></font></p>  	    <p>&nbsp;</p>  	    <p align="center"><font face="verdana" size="2"><b>Yaniel Castro Torres<sup>a*</sup>, Alejandro Emilio Santos Portela<sup>a</sup>, Ildiko Mar&iacute;a Garrido B&#337;sze<sup>b</sup></b></font></p>  	    <p>&nbsp;</p>  	    <p align="justify"><font face="verdana" size="2"><sup>a</sup> <i>Facultad de Medicina, Universidad de Ciencias M&eacute;dicas Dr. Seraf&iacute;n Ruiz de Z&aacute;rate Ruiz, Santa Clara, Villa Clara, Cuba.</i></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><sup>b</sup> <i>Policl&iacute;nico Docente Universitario Jos&eacute; Ram&oacute;n Le&oacute;n Acosta, Santa Clara, Villa Clara, Cuba.</i></font></p>  	    <p>&nbsp;</p>  	    <p align="justify"><font face="verdana" size="2"><b>* Autor para correspondencia:    <br> </b>Universidad de Ciencias M&eacute;dicas &#171;Dr. Seraf&iacute;n Ruiz de Z&aacute;rate Ruiz&#187;,    <br> Luz Caballero #161 entre Hospital y Alejandro Oms, Reparto Parroquia.    <br> Santa Clara, CP 50100 Villa Clara, Cuba,    <br> Tel&eacute;fono: +53 42 272776.    <br> Correos electr&oacute;nicos: <a href="mailto:yanielct@edu.vcl.sld.cu">yanielct@edu.vcl.sld.cu</a>, <a href="mailto:castrotorresy@gmail.com">castrotorresy@gmail.com</a> (Y. Castro Torres).</font></p>  	    <p>&nbsp;</p>  	    <p align="justify"><font face="verdana" size="2">Recibido el 7 de agosto de 2013    ]]></body>
<body><![CDATA[<br> 	Aceptado el 10 de febrero de 2014</font></p>  	    <p>&nbsp;</p>  	    <p align="justify"><font face="verdana" size="2"><b>Resumen</b></font></p>  	    <p align="justify"><font face="verdana" size="2">La hipertensi&oacute;n sensible a sal es el aumento de la presi&oacute;n arterial luego de una sobrecarga salina, como consecuencia esencialmente de una disminuci&oacute;n en la excreci&oacute;n renal de sodio. En los &uacute;ltimos a&ntilde;os, ha sido desarrollada una teor&iacute;a para explicar su origen que tiene como base la inflamaci&oacute;n del tejido renal. El proceso inicia con la producci&oacute;n en los ri&ntilde;ones de radicales libres derivados del metabolismo oxidativo. Luego se desarrolla un mecanismo de inflamaci&oacute;n del intersticio renal por infiltraci&oacute;n de linfocitos T, y otras c&eacute;lulas inmunol&oacute;gicas. Fundamentalmente los linfocitos T incrementan la producci&oacute;n de angiotensina II que estimula la retenci&oacute;n de sodio y agua a este nivel, favoreciendo el desarrollo de hipertensi&oacute;n sensible a sal. La relaci&oacute;n entre infiltraci&oacute;n renal por c&eacute;lulas del sistema inmune e hipertensi&oacute;n sensible a sal permite, en parte, explicar la asociaci&oacute;n entre enfermedades autoinmunes y la hipertensi&oacute;n arterial. El uso de antioxidantes y el dise&ntilde;o de nuevos f&aacute;rmacos pueden ser una alternativa adicional al tratamiento de los pacientes afectados.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Palabras clave:</b> Hipertensi&oacute;n sensible a sal; Estr&eacute;s oxidativo; Inflamaci&oacute;n renal; Linfocitos T; Macr&oacute;fagos; Cuba.</font></p>  	    <p>&nbsp;</p>  	    <p align="justify"><font face="verdana" size="2"><b>Abstract</b></font></p>  	    <p align="justify"><font face="verdana" size="2">Salt&#45;sensitive hypertension is produced by a decrease in salt renal excretion after a salt overload. Over the last few years, a new theory has been developed to explain this condition based on renal tissue inflammation. This process begins with free radicals production in renal tissue due to oxidative metabolism. Then they favor a renal inflammation mechanism with T&#45;lymphocytes infiltration and other immune cells. Essentially, T&#45;lymphocytes determine an increase in angiotensin II production which raises sodium and water retention. Association among autoimmune diseases and hypertension may be explained, in part, by the relationship between salt&#45;sensitive hypertension and renal inflammation. The use of antioxidant drugs and the development of new medicaments may be a choice for treating patients affected with this condition.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Keywords:</b> Salt&#45;sensitive hypertension; Oxidative stress; Renal inflammation; T&#45;lymphocytes; Macrophages; Cuba.</font></p>  	    <p>&nbsp;</p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><b>Introducci&oacute;n</b></font></p>  	    <p align="justify"><font face="verdana" size="2">Actualmente la hipertensi&oacute;n arterial (HTA) representa un problema de salud para gran parte de la poblaci&oacute;n mundial. Se estima que afecta al 25&#45;47% de las personas mayores de 18 a&ntilde;os<sup>1</sup>, y provoca alrededor de 7.6 millones de muertes prematuras anualmente<sup>2</sup>. El aumento de las cifras de presi&oacute;n arterial (PA) por encima de los valores establecidos favorece el incremento en la incidencia de infarto agudo de miocardio, accidentes vasculares encef&aacute;licos, insuficiencia renal, muerte s&uacute;bita y enfermedad vascular perif&eacute;rica<sup>3</sup>.</font></p>  	    <p align="justify"><font face="verdana" size="2">La ingesti&oacute;n excesiva de sal constituye un factor de riesgo para el desarrollo de HTA esencial<sup>4,5</sup>. En pa&iacute;ses donde el consumo de esta sustancia se encuentra entre los 100 y los 500 mEq/d&iacute;a, la incidencia de HTA es mayor, cuando se compara con los que mantienen una dieta inferior a 50 mEq/d&iacute;a<sup>6</sup>. Los mecanismos involucrados incluyen el incremento en el volumen intravascular y la resistencia vascular perif&eacute;rica, debido en parte a la activaci&oacute;n del sistema nervioso simp&aacute;tico<sup>7</sup>.</font></p>  	    <p align="justify"><font face="verdana" size="2">La hipertensi&oacute;n sensible a sal (HSS) es el aumento de la PA luego de una sobrecarga salina, y tiene una frecuencia cercana al 80% en pacientes mayores de 60 a&ntilde;os<sup>8</sup>. Muchas han sido las propuestas para explicar la deficiencia en la excreci&oacute;n urinaria de sal en individuos que desarrollan esta condici&oacute;n<sup>9</sup>, sugiri&eacute;ndose la acci&oacute;n de factores vasoactivos y natriur&eacute;ticos como el &oacute;xido n&iacute;trico, el factor natriur&eacute;tico auricular y el sistema cininas&#45;kalikre&iacute;na<sup>10</sup>. En los &uacute;ltimos a&ntilde;os varios investigadores han centrado su atenci&oacute;n en la relaci&oacute;n entre el estr&eacute;s oxidativo, la infiltraci&oacute;n del intersticio renal por c&eacute;lulas inflamatorias y el desarrollo de HSS. Esto permite plantear nuevas hip&oacute;tesis que explican la relaci&oacute;n entre HTA y enfermedades autoinmunes teniendo como base los mecanismos de la inflamaci&oacute;n renal.</font></p>  	    <p align="justify"><font face="verdana" size="2">La presente revisi&oacute;n se propuso mostrar las evidencias que apoyan la relaci&oacute;n entre la formaci&oacute;n de radicales libres (RL) de ox&iacute;geno y nitr&oacute;geno, la inflamaci&oacute;n del intersticio renal por acci&oacute;n de c&eacute;lulas del sistema inmunol&oacute;gico y la subsiguiente producci&oacute;n de hormonas prohipertensivas que explican el deterioro de la excreci&oacute;n renal de sodio en pacientes con HSS. Igualmente se analizar&aacute;n algunos aspectos en el orden pr&aacute;ctico sobre la base de estos conocimientos, que pueden ser &uacute;tiles en el prop&oacute;sito de alcanzar una reducci&oacute;n en las cifras tensionales en la poblaci&oacute;n tanto hipertensa como no hipertensa.</font></p>  	    <p align="justify">&nbsp;</p> 	    <p align="justify"><font face="verdana" size="2"><b>Hipertensi&oacute;n sensible a sal: concepto y epidemiolog&iacute;a</b></font></p>      <p align="justify"><font face="verdana" size="2">La HSS es el aumento de la PA media mayor de 10 mmHg luego de ingerir una dieta rica en sodio, seguido de un contexto donde existe un aumento en la depleci&oacute;n de este cati&oacute;n debido al uso de diur&eacute;ticos y/o dietas hipos&oacute;dicas<sup>11</sup>. Esta condici&oacute;n al parecer tiene una mayor prevalencia entre individuos en edades avanzadas de la vida. Aproximadamente el 80% de las personas hipertensas mayores de 60 a&ntilde;os padecen HSS, mientras que entre los menores de 40 a&ntilde;os solo la manifiestan el 50%<sup>9</sup>. Ciertos elementos epidemiol&oacute;gicos se han asociado con mayor frecuencia a esta condici&oacute;n, como la raza negra, obesidad, diabetes mellitus, disfunci&oacute;n renal, uso de ciclosporina A y la edad avanzada<sup>12</sup>. Adem&aacute;s existen evidencias de trastornos en la expresi&oacute;n de genes que codifican para el angiotensin&oacute;geno<sup>13</sup>, la enzima convertidora de angiotensina<sup>14</sup>, la renina<sup>15</sup> y la sintetasa de aldosterona<sup>16</sup>. Como vemos todos son elementos que integran el sistema renina&#45;angiotensina&#45;aldosterona que desempe&ntilde;an un papel fundamental en la fisiopatolog&iacute;a de la HSS.</font></p>  	    <p align="justify"><font face="verdana" size="2">Se ha observado que los pacientes con HSS tienen un riesgo incrementado de sufrir da&ntilde;os en &oacute;rganos diana, pues padecen con mayor frecuencia de hipertrofia ventricular izquierda, proteinuria y bloqueo del descenso nocturno de la PA<sup>17</sup>. Estos efectos negativos incrementan la probabilidad de eventos cardiovasculares entre hipertensos con sensibilidad a la sal, en comparaci&oacute;n con los resistentes<sup>18</sup>.</font></p>  	    <p align="justify">&nbsp;</p> 	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><b>El estr&eacute;s oxidativo y su relaci&oacute;n con la hipertensi&oacute;n arterial</b></font></p>      <p align="justify"><font face="verdana" size="2">El conocimiento de los RL y su metabolismo ha permitido descifrar un grupo de funciones que desarrollan estas sustancias en el organismo. Los mismos est&aacute;n integrados a la regulaci&oacute;n del tono vascular, la transducci&oacute;n de se&ntilde;ales y como sensores de la tensi&oacute;n de ox&iacute;geno en los tejidos<sup>19</sup>. Estas funciones se unen a las reconocidas anteriormente en relaci&oacute;n con el da&ntilde;o celular, el c&aacute;ncer y el envejecimiento<sup>20&#150;22</sup>.</font></p>  	    <p align="justify"><font face="verdana" size="2">Existen fundamentalmente 2 variedades de RL: las especies reactivas del ox&iacute;geno y las del nitr&oacute;geno. En las primeras encontramos el super&oacute;xido (O<sub>2</sub><sup>&minus;</sup>), el per&oacute;xido de hidr&oacute;geno (H<sub>2</sub>O<sub>2</sub>) y el i&oacute;n hidroxilo (OH<sup>&minus;</sup>). Una de las principales v&iacute;as para la producci&oacute;n de O<sub>2</sub><sup>&minus;</sup> es a partir de la acci&oacute;n de la enzima NADPH oxidasa sobre el O<sub>2</sub>. Esta enzima se encuentra presente en m&uacute;ltiples c&eacute;lulas del organismo como neutr&oacute;filos<sup>23</sup>, fibroblastos<sup>24</sup>, c&eacute;lulas endoteliales<sup>25</sup> y c&eacute;lulas mesangiales<sup>26</sup>. El H<sub>2</sub>O<sub>2</sub> deriva de la acci&oacute;n de la enzima super&oacute;xido dismutasa sobre el O<sub>2</sub><sup>&minus;</sup>. Finalmente el i&oacute;n OH<sup>&minus;</sup> se origina luego de la reducci&oacute;n del H<sub>2</sub>O<sub>2</sub>, apoyado por la actividad de mol&eacute;culas de hierro<sup>19</sup>.</font></p>  	    <p align="justify"><font face="verdana" size="2">El segundo grupo de RL son las especies reactivas del nitr&oacute;geno, dentro de las que est&aacute;n el cati&oacute;n nitrosonium (NO<sup>+</sup>), el ani&oacute;n nitroxilo (NO<sup>&minus;</sup>) y el peroxinitrato (ONOO<sup>&minus;</sup>). La mayor&iacute;a de estos productos tienen su origen en la interacci&oacute;n de mol&eacute;culas de ox&iacute;geno con el &oacute;xido n&iacute;trico<sup>19</sup>.</font></p>  	    <p align="justify"><font face="verdana" size="2">En condiciones normales existe protecci&oacute;n a los efectos t&oacute;xicos de estos RL por sustancias antioxidantes localizadas tanto intra como extracelulares. Sin embargo, cuando estos mecanismos de defensa fallan, las c&eacute;lulas pasan a un estado conocido como estr&eacute;s oxidativo, desencadenando da&ntilde;os que pueden llegar a ser irreversibles e incluso provocar muerte celular<sup>27,28</sup>.</font></p>  	    <p align="justify"><font face="verdana" size="2">Desde hace a&ntilde;os se conoce que el estr&eacute;s oxidativo desempe&ntilde;a un papel fundamental en la fisiopatolog&iacute;a de la HTA<sup>29</sup>. Varias teor&iacute;as han sido propuestas para explicar esta relaci&oacute;n, pero las m&aacute;s estudiadas son la hemodin&aacute;mica, que determina un aumento en la vasoconstricci&oacute;n arterial, y la estructural, que favorece el remodelado vascular. Los agentes reactivos del ox&iacute;geno pueden provocar un incremento en la vasoconstricci&oacute;n de los vasos sangu&iacute;neos sist&eacute;micos e intrarrenales<sup>30</sup>. Estas sustancias han mostrado capacidad para inactivar el oxido n&iacute;trico endotelial, lo que trae como consecuencia un incremento en la vasoconstricci&oacute;n<sup>31</sup>. Otra propuesta utilizada para explicar el aumento en la PA plantea que los agentes reactivos del ox&iacute;geno pueden incrementar la oxidaci&oacute;n del &aacute;cido araquid&oacute;nico, con la formaci&oacute;n posterior de eicosanoides con propiedades vasoconstrictoras como la prostaglandina F2&#945;<sup>32</sup> y la inhibici&oacute;n en la s&iacute;ntesis de PGI<sub>2</sub><sup>33</sup>. Adicionalmente el O<sub>2</sub><sup>&minus;</sup> estimula la entrada de calcio en las c&eacute;lulas endoteliales<sup>34</sup> y media la acci&oacute;n de otras sustancias vasoconstrictoras como la angiotensina II, tromboxano A<sub>2</sub>, endotelina&#45;1 y la norepinefrina<sup>35</sup>. Por otra parte, se sugiere que las especies del ox&iacute;geno tienen la capacidad de activar una serie de cascadas metab&oacute;licas en las c&eacute;lulas del m&uacute;sculo liso vascular que inducen remodelado de las arterias, lo que provoca rigidez de los vasos y estrechamiento de su luz<sup>36</sup>.</font></p>  	    <p align="justify"><font face="verdana" size="2">Cl&aacute;sicamente estas han sido las teor&iacute;as utilizadas para explicar la influencia del estr&eacute;s oxidativo en la fisiopatolog&iacute;a de la HTA. Sin embargo, en los &uacute;ltimos a&ntilde;os existen evidencias sobre el papel esencial del estr&eacute;s oxidativo en la retenci&oacute;n de sodio y agua en el tejido renal, provocando un incremento en las cifras de PA. La acumulaci&oacute;n de RL en el intersticio renal ha demostrado que favorece la s&iacute;ntesis local de varias citocinas, las que estimulan la infiltraci&oacute;n de c&eacute;lulas del sistema inmunol&oacute;gico. Estas, a su vez, incrementan la producci&oacute;n de hormonas prohipertensivas que llevan al desarrollo de HTA<sup>37</sup>.</font></p>  	    <p align="justify">&nbsp;</p> 	    <p align="justify"><font face="verdana" size="2"><b>Inflamaci&oacute;n renal e hipertensi&oacute;n sensible a sal</b></font></p>      <p align="justify"><font face="verdana" size="2">La infiltraci&oacute;n renal por c&eacute;lulas del sistema inmune y su relaci&oacute;n con el desarrollo de HTA ha sido ampliamente estudiada. Kurokawa<sup>38</sup> y Rodr&iacute;guez&#45;Iturbe et al.<sup>39</sup> descubrieron, en modelos de animales con HSS, una infiltraci&oacute;n significativa de c&eacute;lulas inmunes en diferentes secciones del tejido renal, asociada con altas concentraciones de angiotensina II. Entre los a&ntilde;os 2005 y 2009 un grupo de investigadores demostraron por separado que los linfocitos tienen un sistema renina&#45;angiotensina funcional<sup>40</sup>. En estos estudios se comprueba la expresi&oacute;n en las c&eacute;lulas T de angiotensin&oacute;geno, enzima convertidora de angiotensina, renina, adem&aacute;s de ser capaces de producir niveles fisiol&oacute;gicos de angiotensina II<sup>41</sup>. Esto permite explicar por qu&eacute; la presencia de c&eacute;lulas inmunes a nivel renal favorece la retenci&oacute;n de sodio y agua y secundariamente HTA. Tal es el caso de modelos de HSS, donde la severidad de la HTA se correlaciona con un incremento en los niveles de angiotensina II intrarrenal e infiltraci&oacute;n de c&eacute;lulas inmunes<sup>42</sup>. En sendas investigaciones de Miguel et al.<sup>43,44</sup> muestran que las c&eacute;lulas T favorecen el desarrollo de HSS y da&ntilde;o renal en ratas de laboratorio que presentan HSS. En la segunda de estas encuentran que, unido al incremento en la infiltraci&oacute;n de linfocitos T en el tejido renal de estos animales, la administraci&oacute;n de un agente inmunosupresor como el tacrolimus disminuye la mencionada infiltraci&oacute;n, reduce el estado oxidativo y la expresi&oacute;n renal de la enzima NADPH oxidasa. Esto provoca un descenso de la PA y de los niveles de albuminuria en los animales estudiados, reafirmando la relaci&oacute;n entre inflamaci&oacute;n renal e HSS. Adem&aacute;s establece la posibilidad de reducir los niveles de PA con el uso de f&aacute;rmacos capaces de disminuir la inflamaci&oacute;n y/o la infiltraci&oacute;n de c&eacute;lulas inmunes en el tejido renal.</font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2">Otros estudios corroboran estas observaciones, pero adem&aacute;s abordan la influencia de la angiotensina II formada en el intersticio renal y su posible papel en la inflamaci&oacute;n renal<sup>45</sup>. La angiotensina II del intersticio renal desempe&ntilde;a una funci&oacute;n importante en la regulaci&oacute;n de la microcirculaci&oacute;n renal, la funci&oacute;n tubular y en la patog&eacute;nesis de diversos da&ntilde;os tubulointersticiales<sup>46</sup>. Tambi&eacute;n se han encontrado niveles superiores de angiotensina II en el fluido del intersticio renal que en el plasma sangu&iacute;neo<sup>47,48</sup>, y se ha comprobado que los niveles de angiotensina II en los vasos linf&aacute;ticos renales no aumentan con la administraci&oacute;n de esta sustancia en la circulaci&oacute;n sangu&iacute;nea de la arteria renal, por lo que es posible que la misma se forme intracelularmente y luego se mueva hacia el l&iacute;quido intersticial<sup>49</sup>. A partir de la importancia de la angiotensina II en la fisiopatolog&iacute;a de la HTA, es necesario ampliar las investigaciones sobre la formaci&oacute;n de esta sustancia en el tejido renal, su interacci&oacute;n con otros elementos que participan en la inflamaci&oacute;n renal, y la posible influencia para el desarrollo de HSS.</font></p>  	    <p align="justify"><font face="verdana" size="2">Los macr&oacute;fagos son otras c&eacute;lulas del sistema inmune que han sido relacionadas con las cifras de PA. El v&iacute;nculo entre la inflamaci&oacute;n renal, el desarrollo de HSS y los trabajos que han probado la efectividad del uso de medicamentos inmunosupresores en el control de la PA, sugieren que los macr&oacute;fagos desempe&ntilde;an un rol fundamental en la aparici&oacute;n de HSS. Igualmente existen investigaciones demostrando la continua infiltraci&oacute;n y participaci&oacute;n de estas c&eacute;lulas y los linfocitos T en el proceso de inflamaci&oacute;n del intersticio renal<sup>38</sup>, que desencadena un aumento en la s&iacute;ntesis de angiotensina II y posteriormente un incremento en los valores de la PA. Sin embargo, hay estudios que desaprueban esta teor&iacute;a, pues establecen que los macr&oacute;fagos participan en un mecanismo de defensa adaptativa que minimiza los efectos hipertensivos de la retenci&oacute;n de sodio<sup>50</sup>. Apoyando esta idea, trabajos actuales indican que la depleci&oacute;n de los macr&oacute;fagos favorece el desarrollo de HSS, debido a que estos participan en un mecanismo extrarrenal regulador del sodio intersticial<sup>51</sup>. A&uacute;n se necesitan nuevos estudios para conocer cu&aacute;l es la verdadera funci&oacute;n de estas c&eacute;lulas en el desarrollo de la HSS. Hasta el presente se conoce que formando parte del proceso inflamatorio del tejido renal est&aacute;n asociadas al incremento en las cifras de PA, mientras que a trav&eacute;s de su actividad reguladora del sodio intersticial favorecen la reducci&oacute;n de las cifras tensionales.</font></p>  	    <p align="justify"><font face="verdana" size="2">Existe en la actualidad una teor&iacute;a expuesta por Jonhson et al.<sup>12,52</sup> que plantea la posibilidad de un proceso gradual y continuo en el desarrollo de HSS. Estos autores establecen que la PA sist&eacute;mica elevada de manera continua desencadena da&ntilde;os renales con la formaci&oacute;n de arteriolopat&iacute;a aferente y enfermedad tubulointersticial, estimulando la producci&oacute;n de RL e incrementando la actividad de mol&eacute;culas de adhesi&oacute;n para leucocitos, con la subsiguiente infiltraci&oacute;n de linfocitos T y la activaci&oacute;n del sistema renina&#45;angiotensina&#45;aldosterona. La acci&oacute;n prolongada de estas sustancias lleva a un estado de vasoconstricci&oacute;n en las arteriolas preglomerulares que reduce el filtrado glomerular y por tanto la excreci&oacute;n de sodio y agua, lo que favorece la aparici&oacute;n de HSS. Esta hip&oacute;tesis permite esclarecer por qu&eacute; existen distintos grados de sensibilidad a la sal en diferentes grupos de pacientes, pues esto depende de la intensidad de la afectaci&oacute;n tubulointersticial de cada individuo en relaci&oacute;n con el tiempo de evoluci&oacute;n de la HTA. Adem&aacute;s reafirma el papel de la inflamaci&oacute;n renal en la aparici&oacute;n de HSS, y deja comprender que el da&ntilde;o provocado por la acci&oacute;n prolongada de altas cifras de PA en el tejido renal puede ser en parte el elemento necesario para estimular los procesos inflamatorios a este nivel que posteriormente llevar&aacute;n a la HSS. La predisposici&oacute;n individual a sufrir afectaci&oacute;n del intersticio renal a trav&eacute;s de los mecanismos anteriores puede estar determinada por factores gen&eacute;ticos y ambientales que explicar&iacute;an la complejidad de este tema cuando se estudian diversas poblaciones. Existen estudios demostrando que la angiotensina II producida a partir de la actividad de los linfocitos T posee propiedades proinflamatorias debido a que estimula la liberaci&oacute;n de interleucina&#45;1, interleucina&#45;6 y factor de necrosis tumoral &#945;, tanto a nivel local como sist&eacute;mico<sup>53,54</sup>. Esta secuencia permite plantear la posibilidad de un c&iacute;rculo vicioso (<a href="#f1">fig. 1</a>) que explica por qu&eacute; estudios publicados al respecto muestran una prolongaci&oacute;n de la inflamaci&oacute;n del tejido renal en pacientes hipertensos, incrementando la resistencia de estos a los tratamientos antihipertensivos, y el riesgo de complicaciones futuras<sup>55</sup>.</font></p>  	    <p align="center"><font face="verdana" size="2"><a name="f1"></a></font></p>  	    <p align="center"><font face="verdana" size="2"><img src="/img/revistas/acm/v84n3/a9f1.jpg"></font></p>  	    <p align="justify">&nbsp;</p> 	    <p align="justify"><font face="verdana" size="2"><b>Relaci&oacute;n entre inflamaci&oacute;n renal, hipertensi&oacute;n sensible a sal y trastornos autoinmunes</b></font></p>      <p align="justify"><font face="verdana" size="2">Las enfermedades autoinmunes se caracterizan por aumento en la actividad del sistema inmunol&oacute;gico. Los mecanismos propuestos para explicar el desarrollo de HTA en estas condiciones patol&oacute;gicas son m&uacute;ltiples<sup>56</sup>, por lo que nuestra exposici&oacute;n quedar&aacute; reducida a aquellos que vinculan a estas entidades con la inflamaci&oacute;n renal y el desarrollo de HSS. Kristensen y Andersen<sup>57</sup> hallaron un incremento en anticuerpos s&eacute;ricos y reacciones de hipersensibilidad tard&iacute;a contra ant&iacute;genos vasculares en un grupo de pacientes hipertensos, demostrando un aumento en la reactividad autoinmune en estas personas. Por otra parte, se observa la presencia de efectos antihipertensivos con la depleci&oacute;n de linfocitos<sup>58</sup>, timectom&iacute;a neonatal<sup>59</sup>, uso de sueros antit&iacute;micos<sup>58</sup> y terapia con ciclofosfamida<sup>60</sup> en varios estudios con modelos experimentales de HTA. Rodriguez&#45;Iturbe et al.<sup>61</sup> publicaron un art&iacute;culo en el cual plantean que una actividad autoinmune a las prote&iacute;nas de choque t&eacute;rmico (son chaperones moleculares que estimulan la reactividad autoinmune<sup>62</sup>) expresadas en los ri&ntilde;ones puede ser un mecanismo que facilita un bajo grado de inflamaci&oacute;n tubulointersticial a nivel renal por largos per&iacute;odos de tiempo y que persiste, a pesar del uso de f&aacute;rmacos capaces de disminuir esta condici&oacute;n. Las prote&iacute;nas de choque t&eacute;rmico se invocan en la continuidad del proceso inflamatorio en los ri&ntilde;ones, e incluso, al parecer facilitan su aparici&oacute;n a partir de un mecanismo autoinmine<sup>63</sup>. Esta inflamaci&oacute;n incrementa la producci&oacute;n de angiotensina II en esta zona, aumentando secundariamente los valores de PA. Varios investigadores han encontrado una sobreexpresi&oacute;n de este grupo de prote&iacute;nas en los ri&ntilde;ones de modelos de HSS<sup>64,65</sup>. Igualmente se ha logrado observar un aumento de anticuerpos sangu&iacute;neos contra las prote&iacute;nas de choque t&eacute;rmico 70 y 65 en pacientes hipertensos, reaccionando con sus respectivos ant&iacute;genos en el tejido renal<sup>66</sup>; esto favorece la aparici&oacute;n de procesos inflamatorios que llevan a la HSS como se ha explicado. El estudio de estas prote&iacute;nas puede abrir un nuevo horizonte en la comprensi&oacute;n de la fisiopatolog&iacute;a de algunas enfermedades autoinmunes y espec&iacute;ficamente su relaci&oacute;n con la HTA, pues parece evidente que una actividad autoinmune incrementada favorece su lesi&oacute;n, lo que aumenta la probabilidad de inflamaci&oacute;n del intersticio renal.</font></p>  	    <p align="justify"><font face="verdana" size="2">Apoyando los anteriores estudios, un grupo de investigadores demuestran que existe una reducci&oacute;n en las cifras de PA y en la excreci&oacute;n renal de citocinas en pacientes hipertensos con psoriasis y artritis reumatoide que han sido tratados con mofetil micofenolato<sup>67</sup>. Este medicamento es un inmunosupresor y su mecanismo de acci&oacute;n en la reducci&oacute;n de la PA puede deberse a una disminuci&oacute;n en la inflamaci&oacute;n del intersticio renal. La administraci&oacute;n de lisinopril (inhibidor de la enzima convertidora de la angiotensina) e ICI D8731 (bloqueador de los receptores de angiotensina II) en ratones con HTA espont&aacute;nea, demuestra la capacidad de estos para lograr una normalizaci&oacute;n de la PA, y una reducci&oacute;n significativa en la infiltraci&oacute;n de c&eacute;lulas T en el tejido renal de estos animales comparado con controles<sup>68</sup>.</font></p>  	    <p align="justify">&nbsp;</p> 	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><b>Terapia antioxidante y perspectivas futuras</b></font></p>      <p align="justify"><font face="verdana" size="2">A partir del conocimiento sobre la relaci&oacute;n entre estr&eacute;s oxidativo e HTA, varios estudios con agentes antioxidantes han sido dise&ntilde;ados para lograr una reducci&oacute;n en las cifras de PA, alcanz&aacute;ndose resultados positivos<sup>69&#150;72</sup> (<a href="/img/revistas/acm/v84n3/a9t1.jpg" target="_blank">tabla 1</a>).</font></p>  	    <p align="justify"><font face="verdana" size="2">Sin embargo, existen otros autores que no han encontrado beneficios con la administraci&oacute;n de antioxidantes en la terap&eacute;utica de la HTA<sup>73,74</sup>. Hay aspectos que deben tenerse en cuenta, y que no han sido correctamente evaluados en todos los estudios sobre el uso de antioxidantes en este escenario, lo que explica la existencia de resultados tan diversos. Un primer punto debe ser la posibilidad de una dosis insuficiente de los distintos f&aacute;rmacos antioxidantes utilizados en la pr&aacute;ctica cl&iacute;nica, o que de alguna manera no exista una adecuada correlaci&oacute;n entre la posolog&iacute;a de los medicamentos antioxidantes y la concentraci&oacute;n de los RL en el organismo, pues existen factores que pueden estimular el desarrollo de estr&eacute;s oxidativo como el aumento de metales pesados, xenobi&oacute;ticos, el h&aacute;bito de fumar, la adriamicina, radiaciones ultravioletas, traumatismos y el ejercicio f&iacute;sico extenuante<sup>75</sup>. Estos factores deben ser modificados debido a que su persistencia puede interferir en la eficacia del tratamiento antioxidante. Adem&aacute;s, es necesario diferenciar los niveles de RL hallados a nivel sist&eacute;mico y los presentes en el tejido renal. Estos &uacute;ltimos son los que est&aacute;n directamente involucrados en el proceso de inflamaci&oacute;n renal y, por tanto, en la retenci&oacute;n de sodio y el desarrollo de HSS.</font></p>  	    <p align="justify"><font face="verdana" size="2">En el futuro deben continuar desarroll&aacute;ndose nuevos medicamentos capaces de actuar sobre los mecanismos del estr&eacute;s oxidativo y/o de la inflamaci&oacute;n renal. Esto permitir&iacute;a ampliar nuestro arsenal terap&eacute;utico para lograr un tratamiento m&aacute;s integral de los pacientes con HTA, y espec&iacute;ficamente, aquellos que padecen HSS.</font></p>  	    <p>&nbsp;</p>  	    <p align="justify"><font face="verdana" size="2"><b>Conclusiones</b></font></p>  	    <p align="justify"><font face="verdana" size="2">Existe una relaci&oacute;n demostrada entre el estr&eacute;s oxidativo, inflamaci&oacute;n del intersticio renal y el desarrollo de HSS. La infiltraci&oacute;n de linfocitos T y otras c&eacute;lulas del sistema inmunol&oacute;gico en el tejido renal provoca un aumento en los niveles de angiotensina II, que deriva en un incremento en la retenci&oacute;n de sodio y agua, favoreciendo la aparici&oacute;n de HSS. La relaci&oacute;n entre HTA y enfermedades autoinmunes puede explicarse en parte sobre la base de estos conocimientos. El uso adecuado de medicamentos antioxidantes y el desarrollo de nuevos f&aacute;rmacos en este campo pueden incrementar las opciones terap&eacute;uticas de los pacientes afectados.</font></p>  	    <p>&nbsp;</p>  	    <p align="justify"><font face="verdana" size="2"><b>Conflicto de intereses</b></font></p>  	    <p align="justify"><font face="verdana" size="2">Los autores declaran no tener ning&uacute;n conflicto de intereses.</font></p>  	    ]]></body>
<body><![CDATA[<p>&nbsp;</p>  	    <p align="justify"><font face="verdana" size="2"><b>Bibliograf&iacute;a</b></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">1. Staessen JA, Wang J, Bianchi G, et al. Essential hypertension. Lancet. 2003;361:1629&#150;41.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132614&pid=S1405-9940201400030000900001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">2. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood&#150;pressure&#150;related disease, 2001. Lancet. 2008;371:1513&#150;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132616&pid=S1405-9940201400030000900002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281&#150;357.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132618&pid=S1405-9940201400030000900003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">4. Ardiles L, Mezzano S. Rol del ri&ntilde;&oacute;n en la hipertensi&oacute;n salsensible. Rev Med Chile. 2010;138:862&#150;7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132620&pid=S1405-9940201400030000900004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">5. Hall JE, Granger JP, do Carmo JM, et al. Hypertension: Physiology and pathophysiology. Compr Physiol. 2012;2:2393&#150;442.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132622&pid=S1405-9940201400030000900005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">6. Elliot P, Stamler J, Nichols R, et al. Intersalt revisited: further analysis of 24 hour sodium excretion in blood pressure within and across populations. BMJ. 1996;312:1249&#150;53.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132624&pid=S1405-9940201400030000900006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">7. Guild SJ, McBryde FD, Malpas SC, et al. High dietary salt and angiotensin II chronically increase renal sympathetic nerve activity: A direct telemetric study. Hypertension. 2012;59:614&#150;20.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132626&pid=S1405-9940201400030000900007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">8. Weinberg M, Fineberg N. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension. 1991;18:67&#150;71.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132628&pid=S1405-9940201400030000900008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">9. Franco M, S&aacute;nchez&#150;Lozada LG, Bautista R, et al. Pathophysiology of salt&#150;sensitive hypertension: A new scope of an old problem. Blood Purif. 2008;26:45&#150;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132630&pid=S1405-9940201400030000900009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">10. Herrera Acosta J. Hipertensi&oacute;n arterial dependiente de sal. Arch Cardiol Mex. 2001;71 Supl 1:S76&#150;80.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132632&pid=S1405-9940201400030000900010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">11. Gonz&aacute;lez Toledo R, Franco M. &iquest;Es la hipertensi&oacute;n sensible a sal una enfermedad inflamatoria? Papel de los linfocitos y macr&oacute;fagos. Arch Cardiol Mex. 2012;82:312&#150;9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132634&pid=S1405-9940201400030000900011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">12. Johnson RJ, Herrera JA, Schreiner G, et al. Subtle acquired renal injury as a mechanism of salt&#150;sensitive hypertension. N Engl J Med. 2002;346:913&#150;23.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132636&pid=S1405-9940201400030000900012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">13. Johnson AG, Nguyen TV, Davis D. Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. J Hypertens. 2001;19:1053&#150;60.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132638&pid=S1405-9940201400030000900013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">14. Poch E, Gonz&aacute;lez D, Giner V, et al. Molecular basis of salt sensitivity in human hypertension. Evaluation of reninangiotensin&#150;aldosterone system gene polymorphisms. Hypertension. 2001;38:1204&#150;9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132640&pid=S1405-9940201400030000900014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">15. Shimoike H, Iwai N, Kinoshita M. Genetic analysis of renin gene expression in the central nervous system of spontaneously hypertensive rats. Neurosci Lett. 1997;221:133&#150;6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132642&pid=S1405-9940201400030000900015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">16. Pamies&#150;Andreu E, Ramirez&#150;Lorca R, Stiefel Garc&iacute;a&#150;Junco P, et al. Renin&#150;angiotensin&#150;aldosterone system and G&#150;protein beta&#150;3 subunit gene polymorphisms in salt sensitive essential hypertension. J Hum Hypertens. 2003;17:187&#150;91.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132644&pid=S1405-9940201400030000900016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">17. Weinberger MH, Fineberg NS, Fineberg SE, et al. Salt sensitivity, pulse pressure and death in normal and hypertensive humans. Hypertension. 2001;37:429&#150;32.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132646&pid=S1405-9940201400030000900017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">18. Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997;350:1734&#150;7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132648&pid=S1405-9940201400030000900018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">19. Dr&ouml;ge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47&#150;95.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132650&pid=S1405-9940201400030000900019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">20. Harman D. Ageing: A theory based on free radical and radiation chemistry. J Gerontol. 1956;11:298&#150;300.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132652&pid=S1405-9940201400030000900020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">21. Harman D. The ageing process. Proc Natl Acad Sci U S A. 1981;78:7124&#150;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132654&pid=S1405-9940201400030000900021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">22. Harman D. La teor&iacute;a gerontol&oacute;gica de los radicales libres. Rev Esp Geriatr Gerontol. 2001;36:187.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132656&pid=S1405-9940201400030000900022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">23. Griendling KK, Sorescu D, Ushio&#150;Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res. 2000;86:494&#150;501.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132658&pid=S1405-9940201400030000900023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">24. Jones SA, Wood JD, Coffey MJ, et al. The functional expression of p47&#150;phox and p67&#150;phox may contribute to the generation of superoxide by NADPH oxidase&#150;like system in human fibroblasts. FEBS Lett. 1994;355:178&#150;82.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132660&pid=S1405-9940201400030000900024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">25. Jones SA, O'Donell VB, Wood JD, et al. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol Cell Physiol. 1996;271:C626&#150;34.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132662&pid=S1405-9940201400030000900025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">26. Jones SA, Hancock J, Jones OTG, et al. The expression of NADPH oxidase components in human glomerular mesangial cells: Detection of protein and mRNA for p47phax, p67phax, and p22 phax. J Am Soc Nephrol. 1995;5:1483&#150;91.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132664&pid=S1405-9940201400030000900026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">27. C&eacute;spedes Cabrera T, S&aacute;nchez Serrano D. Algunos aspectos sobre el estr&eacute;s oxidativo, el estado antioxidante y la terapia de suplementaci&oacute;n. Rev Cubana Cardiol. 2000;14:55&#150;60.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132666&pid=S1405-9940201400030000900027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">28. Llacuna L, Mach N. Papel de los antioxidantes en la prevenci&oacute;n del c&aacute;ncer. Rev Esp Nutr Hum Diet. 2012;16:16&#150;24.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132668&pid=S1405-9940201400030000900028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">29. Makino A, Skelton MM, Zou AP, et al. Increased renal medullary oxidative stress produces hypertension. Hypertension. 2002;39:667&#150;72.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132670&pid=S1405-9940201400030000900029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">30. Clerk A, Fuller SJ, Michael A, et al. Stimulation of &#171;stress&#150;activated&#187; mitogen&#150;activated protein kinases/c&#150;Jun N&#150;terminal kinases, and p38 mitogen&#150;activated protein kinases in perfuse rat hearts by oxidative and other stresses. J Biol Chem. 1998;273:7228&#150;34.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132672&pid=S1405-9940201400030000900030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">31. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: Role of oxidant stress. Circ Res. 2000;87:840&#150;4.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132674&pid=S1405-9940201400030000900031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">32. Takahashi K, Nammour TM, Fukunaga M, et al. Glomerular actions of a free radical&#150;generated novel prostaglandin, 8&#150;epiprostaglandin F2&#945; Evidence for interaction with thromboxane A2 receptors. J Clin Invest. 1992;90:136&#150;41.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132676&pid=S1405-9940201400030000900032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">33. Zou MH, Ulrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett. 1996;382:101&#150;4.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132678&pid=S1405-9940201400030000900033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">34. Lounsbury KM, Hu Q, Ziegelstein RC. Calcium signaling and oxidant stress in the vasculature. Free Rad Biol Med. 2000;28:1362&#150;9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132680&pid=S1405-9940201400030000900034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">35. Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol. 2002;282:R335&#150;42.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132682&pid=S1405-9940201400030000900035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">36. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85:753&#150;66.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132684&pid=S1405-9940201400030000900036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">37. Rodriguez&#150;Iturbe B, Quiroz Y, Nava M, et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol. 2002;282:F191&#150;201.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132686&pid=S1405-9940201400030000900037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">38. Kurokawa K. Kidney, salt and hypertension: How and why. Kidney Int. 1996;49 Suppl 55:S46&#150;51.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132688&pid=S1405-9940201400030000900038&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">39. Rodr&iacute;guez&#150;Iturbe B, Pons H, Quiroz Y, et al. Mycophenolate mofetil prevents salt&#150;sensitive hypertension resulting from angiotensin II exposure. Kidney Int. 2001;59:2222&#150;32.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132690&pid=S1405-9940201400030000900039&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2">40. Jurewicz M, McDermott DH, Sechler JL, et al. Human T and natural killer cells posses a functional renin&#150;angiotensin system:    <!-- ref --><br> 	further mechanisms of angiotensin II&#150;induced inflammation. J Am Soc Nephrol. 2007;18:1093&#150;102.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132693&pid=S1405-9940201400030000900040&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">41. Hotch NE, Guzik TJ, Chen W, et al. Regulation of T&#150;cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2009;296:R208&#150;16.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132695&pid=S1405-9940201400030000900041&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">42. Franco M, Mart&iacute;nez F, Quiroz Y, et al. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt&#150;sensitive hypertension. Am J Physiol Reg Integr Comp Physiol. 2007;293:R251&#150;6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132697&pid=S1405-9940201400030000900042&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <p align="justify"><font face="verdana" size="2">43. De Miguel C, Das S, Lund H, et al. T lymphocytes mediate hypertension and kidney damage in Dahl salt&#150;sensitive rats. Am J    <!-- ref --><br> 	Physiol Regul Integr Comp Physiol. 2010;298:R1136&#150;42.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132700&pid=S1405-9940201400030000900043&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">44. De Miguel C, Guo C, Lund H, et al. Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. Am J Physiol Renal Physiol. 2011;300:F734&#150;42.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132702&pid=S1405-9940201400030000900044&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">45. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin converting enzyme inhibition. J Am Soc Nephrol. 2002;13:2207&#150;12.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132704&pid=S1405-9940201400030000900045&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">46. Mitchell KD, Navar LG. Enhanced tubuloglomerular feedback during peritubular infusions of angiotensins I and II. Am J Physiol. 1988;255:F383&#150;90.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132706&pid=S1405-9940201400030000900046&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">47. Wilcox CS, Dzau VJ. Effect of captopril on the release of the components of the renin&#45;&#45;&#45;angiotensin system into plasma and lymph. J Am Soc Nephrol. 1992;2:1241&#150;50.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132708&pid=S1405-9940201400030000900047&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">48. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension. 2002;39:129&#150;34.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132710&pid=S1405-9940201400030000900048&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">49. Bailie MD, Rector Jr FC, Seldin DW. Angiotensin II in arterial and renal venous plasma and renal lymph in the dog. J Clin Invest. 1971;50:119&#150;26.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132712&pid=S1405-9940201400030000900049&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">50. Machnik A, Dhalmann A, Kopp C, et al. Mononuclear phagocyte system depletion blocks interstitial tonicity&#150;responsive enhyancer binding protein/vascular endothelial growth factor C expression and induces salt&#150;sensitive hypertension in rats. Hypertension. 2010;55:755&#150;61.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132714&pid=S1405-9940201400030000900050&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">51. Titze J, Machnik A. Sodium sensing in the interstitium and relationship to hypertension. Curr Opin Nephrol Hypertens. 2010;19:385&#150;92.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132716&pid=S1405-9940201400030000900051&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">52. Johnson RJ, Schreiner JF. Hypothesis: 1. The role of acquired tubulointerstitial disease in the pathogenesis of salt&#150;sensitive hypertension. Kidney Int. 1997;52:1169&#150;79.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132718&pid=S1405-9940201400030000900052&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">53. Brasier AR, Recinos III A, Eledrisi MS. Vascular inflammation and the renin&#150;angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257&#150;66.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132720&pid=S1405-9940201400030000900053&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">54. Sekiguchi K, Li X, Coker M, et al. Cross&#150;regulation between the renin&#150;angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res. 2004;63:433&#150;42.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132722&pid=S1405-9940201400030000900054&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">55. Rodriguez&#150;Iturbe B, Romero F, Johnson RJ. Pathophysiologic mechanisms of salt&#150;dependent hypertension. Am J Kidney Dis. 2007;50:655&#150;72.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132724&pid=S1405-9940201400030000900055&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">56. Ryan MJ. The pathophysiology of hypertension in systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2009;296:R1258&#150;67.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132726&pid=S1405-9940201400030000900056&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">57. Kristensen BO, Andersen PL. Autoantibodies in untreated and treated essential hypertension. Acta Med Scan. 1978;203:55&#150;9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132728&pid=S1405-9940201400030000900057&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">58. Svendsen UG. Evidence for an initial, thymus independent and a chronic, thymus&#150;dependent phase of DOCA and salt hypertension in mice. Acta Path Microbiol Scand A. 1976;84:523&#150;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132730&pid=S1405-9940201400030000900058&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">59. Bataillard P, Freiche JC, Vincent M, et al. Effects of neonatal thymectomy on blood pressure and immunological characteristics of the genetically hypertensive rats of the Lyon strain. J Hypertens. 1986;4 Suppl 3:S5455&#150;67.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132732&pid=S1405-9940201400030000900059&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">60. Khraibi AA, Norman Jr RA, Dzielak DJ. Chronic immunosuppression attenuates hypertension in Okamoto spontaneously hypertensive rats. Am J Physiol. 1984;247:H722&#150;6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132734&pid=S1405-9940201400030000900060&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">61. Rodr&iacute;guez&#150;Iturbe B, Vaziri ND, Herrera&#150;Acosta J, et al. Oxidative stress, renal infiltration of immune cells and salt&#150;sensitive hypertension: All for one and one for all. Am J Physiol Renal Physiol. 2004;286:F606&#150;16.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132736&pid=S1405-9940201400030000900061&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">62. Kaufmann SHE. Heat shock proteins and the immune response. Immunol Today. 1990;11:129&#150;36.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132738&pid=S1405-9940201400030000900062&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">63. Pons H, Ferrebuz A, Quiroz Y, et al. Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt&#150;sensitive hypertension. Am J Physiol Renal Physiol. 2013;304:F289&#150;99.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132740&pid=S1405-9940201400030000900063&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">64. Ishizaka N, Aizawa T, Ohno M, et al. Regulation and localization of HSP70 and HSP25 in the kidney of rats undergoing long&#150;term administration of angiotensin II. Hypertension. 2002;39:122&#150;8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132742&pid=S1405-9940201400030000900064&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">65. Bravo J, Quiroz Y, Pons H, et al. Vimentin and heat shock protein expression are induced in the kidney by angiotensin and by nitric oxide inhibition. Kidney Int. 2003;64 Suppl 86:S46&#150;51.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132744&pid=S1405-9940201400030000900065&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">66. Pockley AG, de Faire U, Kiessling R, et al. Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens. 2002;20:1815&#150;20.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132746&pid=S1405-9940201400030000900066&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">67. Herrera J, Ferrebuz A, MacGregor EG, et al. Mycophenolate mofetil improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006;17 Suppl 3:S218&#150;25.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132748&pid=S1405-9940201400030000900067&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">68. Geiger H, Fierlbeck W, Mai M, et al. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. Kidney Int. 1997;51:750&#150;61.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132750&pid=S1405-9940201400030000900068&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">69. Chen J, He J, Hamm L, et al. Serum antioxidant vitamins and blood pressure in the United States population. Hypertension. 2002;40:810&#150;6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132752&pid=S1405-9940201400030000900069&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">70. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117&#150;24.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132754&pid=S1405-9940201400030000900070&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">71. Rodrigo R, Prat H, Passalacqua J, et al. Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension. Clin Sci (Lond). 2008;114:625&#150;34.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132756&pid=S1405-9940201400030000900071&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">72. Rodrigo R, Prat H, Passalacqua J, et al. Relationship between oxidative stress and essential hypertension. Hypertens Res. 2007;30:1159&#150;67.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132758&pid=S1405-9940201400030000900072&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">73. Kim MK, Sasaki S, Sasazuki S, et al. Lack of long&#150;term effect of vitamin C supplementation on blood pressure. Hypertension. 2002;40:797&#150;803.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132760&pid=S1405-9940201400030000900073&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">74. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high&#150;risk individuals: A randomized placebo&#150;controlled trial. Lancet. 2002;360:23&#150;33.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132762&pid=S1405-9940201400030000900074&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">75. Guti&eacute;rrez Maydata A. Radicales libres derivados del ox&iacute;geno y estr&eacute;s oxidativo. En: Caballero L&oacute;pez A, editor. Terapia intensiva., 1, 2.&ordf; ed. La Habana: Ciencias M&eacute;dicas; 2006. p. 169&#150;74.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1132764&pid=S1405-9940201400030000900075&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Staessen]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bianchi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Essential hypertension]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>361</volume>
<page-range>1629-41</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawes]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Vander Hoorn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rodgers]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Global burden of blood-pressure-related disease, 2001]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<volume>371</volume>
<page-range>1513-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fagard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Narkiewicz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[2013 ESH/ESC guidelines for the management of arterial hypertension]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2013</year>
<volume>31</volume>
<page-range>1281-357</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ardiles]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mezzano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Rol del riñón en la hipertensión salsensible]]></article-title>
<source><![CDATA[Rev Med Chile]]></source>
<year>2010</year>
<volume>138</volume>
<page-range>862-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[do Carmo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hypertension: Physiology and pathophysiology]]></article-title>
<source><![CDATA[Compr Physiol]]></source>
<year>2012</year>
<volume>2</volume>
<page-range>2393-442</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliot]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Stamler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Intersalt revisited: further analysis of 24 hour sodium excretion in blood pressure within and across populations]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1996</year>
<volume>312</volume>
<page-range>1249-53</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guild]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[McBryde]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
<name>
<surname><![CDATA[Malpas]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High dietary salt and angiotensin II chronically increase renal sympathetic nerve activity: A direct telemetric study]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2012</year>
<volume>59</volume>
<page-range>614-20</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weinberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fineberg]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sodium and volume sensitivity of blood pressure. Age and pressure change over time]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>1991</year>
<volume>18</volume>
<page-range>67-71</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Lozada]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Bautista]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pathophysiology of salt-sensitive hypertension: A new scope of an old problem]]></article-title>
<source><![CDATA[Blood Purif]]></source>
<year>2008</year>
<volume>26</volume>
<page-range>45-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera Acosta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Hipertensión arterial dependiente de sal]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2001</year>
<volume>71</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S76-80</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Toledo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[¿Es la hipertensión sensible a sal una enfermedad inflamatoria? Papel de los linfocitos y macrófagos]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2012</year>
<volume>82</volume>
<page-range>312-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Schreiner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Subtle acquired renal injury as a mechanism of salt-sensitive hypertension]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>346</volume>
<page-range>913-23</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[TV]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2001</year>
<volume>19</volume>
<page-range>1053-60</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poch]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Giner]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Molecular basis of salt sensitivity in human hypertension. Evaluation of reninangiotensin-aldosterone system gene polymorphisms]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2001</year>
<volume>38</volume>
<page-range>1204-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimoike]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Iwai]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kinoshita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Genetic analysis of renin gene expression in the central nervous system of spontaneously hypertensive rats]]></article-title>
<source><![CDATA[Neurosci Lett]]></source>
<year>1997</year>
<volume>221</volume>
<page-range>133-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pamies-Andreu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ramirez-Lorca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Stiefel García-Junco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Renin-angiotensin-aldosterone system and G-protein beta-3 subunit gene polymorphisms in salt sensitive essential hypertension]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>2003</year>
<volume>17</volume>
<page-range>187-91</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weinberger]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Fineberg]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Fineberg]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Salt sensitivity, pulse pressure and death in normal and hypertensive humans]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2001</year>
<volume>37</volume>
<page-range>429-32</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morimoto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Uzu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fujii]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sodium sensitivity and cardiovascular events in patients with essential hypertension]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1997</year>
<volume>350</volume>
<page-range>1734-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dröge]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Free radicals in the physiological control of cell function]]></article-title>
<source><![CDATA[Physiol Rev]]></source>
<year>2002</year>
<volume>82</volume>
<page-range>47-95</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ageing: A theory based on free radical and radiation chemistry]]></article-title>
<source><![CDATA[J Gerontol]]></source>
<year>1956</year>
<volume>11</volume>
<page-range>298-300</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The ageing process]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>1981</year>
<volume>78</volume>
<page-range>7124-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[La teoría gerontológica de los radicales libres]]></article-title>
<source><![CDATA[Rev Esp Geriatr Gerontol]]></source>
<year>2001</year>
<volume>36</volume>
<page-range>187</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griendling]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Sorescu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ushio-Fukai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[NAD(P)H oxidase: Role in cardiovascular biology and disease]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2000</year>
<volume>86</volume>
<page-range>494-501</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Coffey]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The functional expression of p47-phox and p67-phox may contribute to the generation of superoxide by NADPH oxidase-like system in human fibroblasts]]></article-title>
<source><![CDATA[FEBS Lett]]></source>
<year>1994</year>
<volume>355</volume>
<page-range>178-82</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[O'Donell]]></surname>
<given-names><![CDATA[VB]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Expression of phagocyte NADPH oxidase components in human endothelial cells]]></article-title>
<source><![CDATA[Am J Physiol Cell Physiol]]></source>
<year>1996</year>
<volume>271</volume>
<page-range>C626-34</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Hancock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[OTG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The expression of NADPH oxidase components in human glomerular mesangial cells: Detection of protein and mRNA for p47phax, p67phax, and p22 phax]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>1995</year>
<volume>5</volume>
<page-range>1483-91</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Céspedes Cabrera]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Serrano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Algunos aspectos sobre el estrés oxidativo, el estado antioxidante y la terapia de suplementación]]></article-title>
<source><![CDATA[Rev Cubana Cardiol]]></source>
<year>2000</year>
<volume>14</volume>
<page-range>55-60</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llacuna]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mach]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Papel de los antioxidantes en la prevención del cáncer]]></article-title>
<source><![CDATA[Rev Esp Nutr Hum Diet]]></source>
<year>2012</year>
<volume>16</volume>
<page-range>16-24</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Skelton]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Increased renal medullary oxidative stress produces hypertension]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2002</year>
<volume>39</volume>
<page-range>667-72</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clerk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fuller]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Michael]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Stimulation of «stress-activated» mitogen-activated protein kinases/c-Jun N-terminal kinases, and p38 mitogen-activated protein kinases in perfuse rat hearts by oxidative and other stresses]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>1998</year>
<volume>273</volume>
<page-range>7228-34</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Endothelial dysfunction in cardiovascular diseases: Role of oxidant stress]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2000</year>
<volume>87</volume>
<page-range>840-4</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nammour]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Fukunaga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Glomerular actions of a free radical-generated novel prostaglandin, 8-epiprostaglandin F2&#945; Evidence for interaction with thromboxane A2 receptors]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1992</year>
<volume>90</volume>
<page-range>136-41</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Ulrich]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase]]></article-title>
<source><![CDATA[FEBS Lett]]></source>
<year>1996</year>
<volume>382</volume>
<page-range>101-4</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lounsbury]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Ziegelstein]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Calcium signaling and oxidant stress in the vasculature]]></article-title>
<source><![CDATA[Free Rad Biol Med]]></source>
<year>2000</year>
<volume>28</volume>
<page-range>1362-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schnackenberg]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature]]></article-title>
<source><![CDATA[Am J Physiol Regul Integr Comp Physiol]]></source>
<year>2002</year>
<volume>282</volume>
<page-range>R335-42</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kunsch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Medford]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oxidative stress as a regulator of gene expression in the vasculature]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>1999</year>
<volume>85</volume>
<page-range>753-66</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez-Iturbe]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nava]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats]]></article-title>
<source><![CDATA[Am J Physiol Renal Physiol]]></source>
<year>2002</year>
<volume>282</volume>
<page-range>F191-201</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kurokawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Kidney, salt and hypertension: How and why]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>1996</year>
<volume>49</volume>
<numero>^s55</numero>
<issue>^s55</issue>
<supplement>55</supplement>
<page-range>S46-51</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Iturbe]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pons]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2001</year>
<volume>59</volume>
<page-range>2222-32</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jurewicz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Sechler]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Human T and natural killer cells posses a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2007</year>
<volume>18</volume>
<page-range>1093-102</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hotch]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Guzik]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Regulation of T-cell function by endogenously produced angiotensin II]]></article-title>
<source><![CDATA[Am J Physiol Regul Integr Comp Physiol]]></source>
<year>2009</year>
<volume>296</volume>
<page-range>R208-16</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension]]></article-title>
<source><![CDATA[Am J Physiol Reg Integr Comp Physiol]]></source>
<year>2007</year>
<volume>293</volume>
<page-range>R251-6</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Miguel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats]]></article-title>
<source><![CDATA[Am J Physiol Regul Integr Comp Physiol]]></source>
<year>2010</year>
<volume>298</volume>
<page-range>R1136-42</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Miguel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease]]></article-title>
<source><![CDATA[Am J Physiol Renal Physiol]]></source>
<year>2011</year>
<volume>300</volume>
<page-range>F734-42</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishiyama]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Seth]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Navar]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin converting enzyme inhibition]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2002</year>
<volume>13</volume>
<page-range>2207-12</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Navar]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Enhanced tubuloglomerular feedback during peritubular infusions of angiotensins I and II]]></article-title>
<source><![CDATA[Am J Physiol]]></source>
<year>1988</year>
<volume>255</volume>
<page-range>F383-90</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilcox]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Dzau]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of captopril on the release of the components of the renin-angiotensin system into plasma and lymph]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>1992</year>
<volume>2</volume>
<page-range>1241-50</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishiyama]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Seth]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Navar]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2002</year>
<volume>39</volume>
<page-range>129-34</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailie]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Rector Jr]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Seldin]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Angiotensin II in arterial and renal venous plasma and renal lymph in the dog]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1971</year>
<volume>50</volume>
<page-range>119-26</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machnik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dhalmann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kopp]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhyancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2010</year>
<volume>55</volume>
<page-range>755-61</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Titze]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Machnik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sodium sensing in the interstitium and relationship to hypertension]]></article-title>
<source><![CDATA[Curr Opin Nephrol Hypertens]]></source>
<year>2010</year>
<volume>19</volume>
<page-range>385-92</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schreiner]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hypothesis: 1. The role of acquired tubulointerstitial disease in the pathogenesis of salt-sensitive hypertension]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>1997</year>
<volume>52</volume>
<page-range>1169-79</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brasier]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Recinos III]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eledrisi]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Vascular inflammation and the renin-angiotensin system]]></article-title>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>2002</year>
<volume>22</volume>
<page-range>1257-66</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sekiguchi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Coker]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure]]></article-title>
<source><![CDATA[Cardiovasc Res]]></source>
<year>2004</year>
<volume>63</volume>
<page-range>433-42</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez-Iturbe]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pathophysiologic mechanisms of salt-dependent hypertension]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2007</year>
<volume>50</volume>
<page-range>655-72</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The pathophysiology of hypertension in systemic lupus erythematosus]]></article-title>
<source><![CDATA[Am J Physiol Regul Integr Comp Physiol]]></source>
<year>2009</year>
<volume>296</volume>
<page-range>R1258-67</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kristensen]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autoantibodies in untreated and treated essential hypertension]]></article-title>
<source><![CDATA[Acta Med Scan]]></source>
<year>1978</year>
<volume>203</volume>
<page-range>55-9</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Svendsen]]></surname>
<given-names><![CDATA[UG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Evidence for an initial, thymus independent and a chronic, thymus-dependent phase of DOCA and salt hypertension in mice]]></article-title>
<source><![CDATA[Acta Path Microbiol Scand A]]></source>
<year>1976</year>
<volume>84</volume>
<page-range>523-8</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bataillard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Freiche]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of neonatal thymectomy on blood pressure and immunological characteristics of the genetically hypertensive rats of the Lyon strain]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>1986</year>
<volume>4</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S5455-67</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khraibi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Norman Jr]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Dzielak]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Chronic immunosuppression attenuates hypertension in Okamoto spontaneously hypertensive rats]]></article-title>
<source><![CDATA[Am J Physiol]]></source>
<year>1984</year>
<volume>247</volume>
<page-range>H722-6</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Iturbe]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vaziri]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera-Acosta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oxidative stress, renal infiltration of immune cells and salt-sensitive hypertension: All for one and one for all]]></article-title>
<source><![CDATA[Am J Physiol Renal Physiol]]></source>
<year>2004</year>
<volume>286</volume>
<page-range>F606-16</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaufmann]]></surname>
<given-names><![CDATA[SHE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Heat shock proteins and the immune response]]></article-title>
<source><![CDATA[Immunol Today]]></source>
<year>1990</year>
<volume>11</volume>
<page-range>129-36</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pons]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrebuz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt-sensitive hypertension]]></article-title>
<source><![CDATA[Am J Physiol Renal Physiol]]></source>
<year>2013</year>
<volume>304</volume>
<page-range>F289-99</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ishizaka]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Aizawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ohno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Regulation and localization of HSP70 and HSP25 in the kidney of rats undergoing long-term administration of angiotensin II]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2002</year>
<volume>39</volume>
<page-range>122-8</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Pons]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Vimentin and heat shock protein expression are induced in the kidney by angiotensin and by nitric oxide inhibition]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2003</year>
<volume>64</volume>
<numero>^s86</numero>
<issue>^s86</issue>
<supplement>86</supplement>
<page-range>S46-51</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pockley]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[de Faire]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Kiessling]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Circulating heat shock protein and heat shock protein antibody levels in established hypertension]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>1815-20</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrebuz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MacGregor]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mycophenolate mofetil improves hypertension in patients with psoriasis and rheumatoid arthritis]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2006</year>
<volume>17</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S218-25</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geiger]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fierlbeck]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Mai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>1997</year>
<volume>51</volume>
<page-range>750-61</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hamm]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Serum antioxidant vitamins and blood pressure in the United States population]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2002</year>
<volume>40</volume>
<page-range>810-6</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Appel]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Obarzanek]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>336</volume>
<page-range>1117-24</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Prat]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Passalacqua]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension]]></article-title>
<source><![CDATA[Clin Sci (Lond)]]></source>
<year>2008</year>
<volume>114</volume>
<page-range>625-34</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Prat]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Passalacqua]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Relationship between oxidative stress and essential hypertension]]></article-title>
<source><![CDATA[Hypertens Res]]></source>
<year>2007</year>
<volume>30</volume>
<page-range>1159-67</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Sasaki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sasazuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lack of long-term effect of vitamin C supplementation on blood pressure]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2002</year>
<volume>40</volume>
<page-range>797-803</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<collab>Heart Protection Study Collaborative Group</collab>
<article-title xml:lang="en"><![CDATA[MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomized placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>360</volume>
<page-range>23-33</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutiérrez Maydata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Radicales libres derivados del oxígeno y estrés oxidativo]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Caballero López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Terapia intensiva]]></source>
<year>2006</year>
<edition>2.ª</edition>
<page-range>169-74</page-range><publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
